A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. (Q38777644)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Daniel Roberts

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

publication date

1 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

771-793

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Personalized pharmacogenomics: predicting efficacy and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Pharmacogenetic tests: the need for a level playing field

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

A systematic review of cost-effectiveness analyses of pharmacogenomic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Systematic review of pharmacoeconomic studies of pharmacogenomic tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of screening forHLA-A*31:01prior to initiation of carbamazepine in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Economic impact of a genetic test for cisplatin-induced ototoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

A pharmacogenetic versus a clinical algorithm for warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

A randomized trial of genotype-guided dosing of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost effectiveness of pharmacogenomics: a critical and systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Cost-effectiveness analysis in pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

The role of cost-effectiveness analysis in the era of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

The Cost-Effectiveness of a Pharmacogenetic Test: A Trial-Based Evaluation of TPMT Genotyping for Azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-016-0397-9

Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.

21 January 2018

1 reference

12 December 2020

Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case

1 reference

12 December 2020

The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.

1 reference

12 December 2020

Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate.

1 reference

12 December 2020

CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

1 reference

12 December 2020

Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy

1 reference

12 December 2020

Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine

1 reference

12 December 2020

The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation

1 reference

12 December 2020

Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.

1 reference

12 December 2020

Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events

1 reference

12 December 2020

Screening for factor V Leiden mutation before prescribing combination oral contraceptives

1 reference

12 December 2020

Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea.

1 reference

12 December 2020

Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore

1 reference

12 December 2020

A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia

1 reference

12 December 2020

Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease

1 reference

12 December 2020

10.1007/S40273-016-0397-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26984520%20AND%20SRC:MED&resulttype=core&format=json